Cargando…
Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study
There is no published study from India on hepatitis C virus (HCV) treatment in dialysis patients. Patients on dialysis with HCV infection treated with pegylated interferon (Peg-INF) monotherapy were studied. All patients were subjected to HCV-polymerase chain reaction, viral load, genotype, and live...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964683/ https://www.ncbi.nlm.nih.gov/pubmed/27512295 http://dx.doi.org/10.4103/0971-4065.172228 |
_version_ | 1782445155333177344 |
---|---|
author | Agarwal, S. K. Bhowmik, D. Mahajan, S. Bagchi, S. |
author_facet | Agarwal, S. K. Bhowmik, D. Mahajan, S. Bagchi, S. |
author_sort | Agarwal, S. K. |
collection | PubMed |
description | There is no published study from India on hepatitis C virus (HCV) treatment in dialysis patients. Patients on dialysis with HCV infection treated with pegylated interferon (Peg-INF) monotherapy were studied. All patients were subjected to HCV-polymerase chain reaction, viral load, genotype, and liver biopsy. Quantitative HCV-RNA was performed monthly. Patients with genotype 1 and 4 were given 12 month therapy while those with genotypes 2 and 3 were given 6 months therapy. Response was classified as per standard criteria of rapid virological response (RVR), early virological response (EVR), end of treatment response (ETR), and sustained virological response (SVR). A total of 85 patients were treated. Mean age was 35.2 ± 10.5 (range 15–67) years, and 77.6% were males. HCV genotypes were 1 in 40.9%, 2 in 12%, 3 in 36.1%, 4 in 3.6%, and others in 7.2%. Mean viral load was 10(6) copies/mL. Mean liver biopsy grade was 4 ± 1.7 and stage 0.8 ± 0.8. Mean time from diagnosis of HCV infection and the treatment start was 10.7 ± 14.3 months. One patient died of unrelated illness, one was lost to follow-up, and three could not sustain treatment due to cost. Forty-three of the 80 (54%) patients had RVR while 49 (61%) patients had EVR and ETR. There was no difference in term of RVR related to genotype. Fifty -four percentage had SVR. Mild flu-like symptoms were seen in all patients. Sixty-four (80%) patients required increase in erythropoietin doses. Twenty-eight (35%) patients developed leukopenia (three treatment-limiting) and 16 (20%) developed thrombocytopenia (one treatment-limiting). Five patients developed tuberculosis, five bacterial pneumonia, and one bacterial knee monoarthritis. None of the patients developed depression. Our study concludes that Peg-INF monotherapy resulted in 54% RVR and SVR in dialysis patients with HCV infection. Therapy was well-tolerated with minimal side effects. There was no effect of viral genotype on response to therapy. |
format | Online Article Text |
id | pubmed-4964683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49646832016-08-10 Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study Agarwal, S. K. Bhowmik, D. Mahajan, S. Bagchi, S. Indian J Nephrol Original Article There is no published study from India on hepatitis C virus (HCV) treatment in dialysis patients. Patients on dialysis with HCV infection treated with pegylated interferon (Peg-INF) monotherapy were studied. All patients were subjected to HCV-polymerase chain reaction, viral load, genotype, and liver biopsy. Quantitative HCV-RNA was performed monthly. Patients with genotype 1 and 4 were given 12 month therapy while those with genotypes 2 and 3 were given 6 months therapy. Response was classified as per standard criteria of rapid virological response (RVR), early virological response (EVR), end of treatment response (ETR), and sustained virological response (SVR). A total of 85 patients were treated. Mean age was 35.2 ± 10.5 (range 15–67) years, and 77.6% were males. HCV genotypes were 1 in 40.9%, 2 in 12%, 3 in 36.1%, 4 in 3.6%, and others in 7.2%. Mean viral load was 10(6) copies/mL. Mean liver biopsy grade was 4 ± 1.7 and stage 0.8 ± 0.8. Mean time from diagnosis of HCV infection and the treatment start was 10.7 ± 14.3 months. One patient died of unrelated illness, one was lost to follow-up, and three could not sustain treatment due to cost. Forty-three of the 80 (54%) patients had RVR while 49 (61%) patients had EVR and ETR. There was no difference in term of RVR related to genotype. Fifty -four percentage had SVR. Mild flu-like symptoms were seen in all patients. Sixty-four (80%) patients required increase in erythropoietin doses. Twenty-eight (35%) patients developed leukopenia (three treatment-limiting) and 16 (20%) developed thrombocytopenia (one treatment-limiting). Five patients developed tuberculosis, five bacterial pneumonia, and one bacterial knee monoarthritis. None of the patients developed depression. Our study concludes that Peg-INF monotherapy resulted in 54% RVR and SVR in dialysis patients with HCV infection. Therapy was well-tolerated with minimal side effects. There was no effect of viral genotype on response to therapy. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4964683/ /pubmed/27512295 http://dx.doi.org/10.4103/0971-4065.172228 Text en Copyright: © 2016 Indian Journal of Nephrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Agarwal, S. K. Bhowmik, D. Mahajan, S. Bagchi, S. Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title | Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title_full | Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title_fullStr | Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title_full_unstemmed | Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title_short | Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study |
title_sort | pegylated interferon monotherapy for hepatitis c virus infection in patients on hemodialysis: a single center study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964683/ https://www.ncbi.nlm.nih.gov/pubmed/27512295 http://dx.doi.org/10.4103/0971-4065.172228 |
work_keys_str_mv | AT agarwalsk pegylatedinterferonmonotherapyforhepatitiscvirusinfectioninpatientsonhemodialysisasinglecenterstudy AT bhowmikd pegylatedinterferonmonotherapyforhepatitiscvirusinfectioninpatientsonhemodialysisasinglecenterstudy AT mahajans pegylatedinterferonmonotherapyforhepatitiscvirusinfectioninpatientsonhemodialysisasinglecenterstudy AT bagchis pegylatedinterferonmonotherapyforhepatitiscvirusinfectioninpatientsonhemodialysisasinglecenterstudy |